title: Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis.
abstract: Hypertrophic pulmonary osteoarthropathy (HPOA) may complicate the advanced lung disease that is associated with cystic fibrosis, resulting in severe joint pain and early-morning stiffness. Symptoms are usually controlled with the administration of nonsteroidal anti-inflammatory drugs, physiotherapy, and, on occasions, oral corticosteroids. This report describes a case of refractory HPOA with complete remission following the administration of IV pamidronate, which is a potent inhibitor of osteoclastic bone resorption. Symptom relief resulted for up to 3 months, but repeated courses of pamidronate have been required to maintain symptom control.
authors.affiliation: Adult Cystic Fibrosis Unit and University of Queensland, The Prince Charles Hospital, Brisbane, Australia.
authors.forename: Luke A
authors.initials: LA
authors.lastname: Garske
authors.forename: Scott C
authors.initials: SC
authors.lastname: Bell
mesh_terms: D000328:Adult; D000842:Ankle / Q000000981:diagnostic imaging; D003550:Cystic Fibrosis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D010005:Osteoarthropathy, Secondary Hypertrophic / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010010:Osteoclasts / Q000187:drug effects; D000077268:Pamidronate; D011859:Radiography
chemical_list: D004164:Diphosphonates; D000077268:Pamidronate